Feedback / Questions
ALY-301 - Alys Pharma
https://www.prnewswire.com/news-releases/alys-pharmaceuticals-doses-first-subject-in-phase-11b-trial-of-aly-301-a-first-in-class-mast-cell-selective-c-kit-inhibitor-for-chronic-urticaria-302598702.html
Oct 30, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next